Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?
- 29 Downloads
Purpose of Review
Identification of targetable mutations such as EGFR has allowed opportunity for Tyrosine Kinase Inhibitor (TKI) therapy for lung cancer treatment. EGFR-TKIs have revolutionized treatment of advanced EGFR mutant Non-Small Cell Lung Cancer (NSCLC), but there is little evidence that EGFR-TKI treatment is effective in stage III NSCLC. Here we discuss recent evidence supporting the use of EGFR-TKI therapy in combination with chemotherapy and radiation in stage III NSCLC.
Recent results of small trials testing EGFR-TKI therapy in combination with chemoradiation showed promising efficacy, improved outcomes, and a tolerable toxicity profile when administered to patients with EGFR mutant stage III NSCLC. However, strong supporting evidence regarding EGFR-TKI therapy in stage III NSCLC is lacking because previous trials involved a small patient population or were terminated due to slow participant accrual.
Despite the lack of large randomized clinical trials, results from early-stage trials highlight promising future directions for investigating the use of EGFR-TKI therapy in stage III NSCLC treatment.
KeywordsNSCLC Stage III EGFR Tyrosine kinase inhibitor Chemoradiation
Compliance with Ethical Standards
Conflict of Interest
Sanjal Desai declares that she has no conflict of interest. Chul Kim received one-time travel support from Caris Life Sciences to an advisory board meeting in 2017; is the site PI for the CANOPY-1 trial (NCT03631199), funded by Novartis; and has received research support from AstraZeneca for an investigator-initiated trial of durvalumab in patients with viral infection and NSCLC. Irina Veytsman declares that she has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46. https://doi.org/10.1016/S1470-2045(11)70393-X. CrossRefPubMedGoogle Scholar
- 11••.Xing L, Wu G, Wang L, et al. A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutation. J Clin Oncol. 2017;35(15_suppl):8531 Randomized clinical trial that directly compares and indicates higher efficacy of neoadjuvant EGFR TKI in EGFR-mutant stage III NSCLC. CrossRefGoogle Scholar
- 12•.Lee Y, Han JY, Moon SH, et al. Incorporating erlotinib or irinotecan plus cisplatin into chemoradiotherapy for stage iii non-small cell lung cancer according to EGFR mutation status. Cancer Res Treat. 2017;49(4):981–9. https://doi.org/10.4143/crt.2016.522 Small sample size study comparing Erlotinib chemoradiation to radiation alone in stage III NSCLC. CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26(15):2450–6. https://doi.org/10.1200/JCO.2007.14.4824.CrossRefPubMedGoogle Scholar
- 15.Komaki R, Allen PK, Wei X, et al. Adding erlotinib to chemoradiation improves overall survival but not progression-free survival in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2015;92(2):317–24. https://doi.org/10.1016/j.ijrobp.2015.02.005.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Casal J, Vasquez S, Leon L, et al. Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC): a Galician lung cancer group phase II study. J Clin Oncol. 2009;27(15_suppl):7537.Google Scholar
- 17.Levy A, Bardet E, Lacas B, et al. A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer. Oncotarget. 2017;8(9):15924–33. https://doi.org/10.18632/oncotarget.12741.CrossRefPubMedGoogle Scholar
- 20.Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–74. https://doi.org/10.1200/JCO.2010.33.4235.CrossRefPubMedGoogle Scholar
- 23.Evans M, O’Sullivan B, Smith M, et al. Large-scale EGFR mutation testing in clinical practice: analysis of a series of 18,920 non-small cell lung cancer cases. Pathol Oncol Res. 2018. https://doi.org/10.1007/s12253-018-0460-2.
- 27••.Zhong W, Wu Y, Chen K, et al. CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non-small cell lung cancer (EMERGING): a randomised study. Ann Oncol 2018;29(8). doi: https://doi.org/10.1093/annonc/mdy424.058. Randomized trial comparing Erlotinib to standard of care chemotherapy in stage III NSCLC and indicates improved outcomes with Erlotinib.
- 29.Lee CK, Man J, Lord S, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):210–6. https://doi.org/10.1001/jamaoncol.2017.4427.CrossRefPubMedGoogle Scholar